News | August 02, 2021
Granules India earmarks Rs 400 crore as Capex for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
India business is growing as per projections; whereas US business will bounce back soon.
Turnover of API division of ISLL stood at Rs 856.58 crore
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Price band in the range of Rs 933 to Rs 954
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company has already embarked upon significant expansion in Turkey
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Subscribe To Our Newsletter & Stay Updated
